ArticleAntimicrobial agents and chemotherapy2012
NDM-4 metallo-β-lactamase with increased carbapenemase activity from Escherichia coli.
Article in Antimicrobial agents and chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Structural basis for carbapenem-hydrolyzing mechanisms of carbapenemases conferring antibiotic resistance.International journal of molecular sciences · 2015Pooled it
- Occurrence of blaBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Clinically Significant Carbapenemases in Gram-Negative Pathogens: Molecular Diversity and Advances in β-Lactamase Inhibitor Therapy.Antibiotics (Basel, Switzerland) · 2026Review
- Genotypic and phenotypic characterization of Pseudomonas aeruginosa PAV112: a virulent clinical strain causing severe pneumonia and lethal sepsis in a murine infection model.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Emergence of a novel NDM-4-producingIDCases · 2026Article
- Structural insights into the activity of carbapenemases: understanding the mechanism of action of current inhibitors and informing the design of new carbapenem adjuvants.RSC medicinal chemistry · 2025Review
- Phytosterols as inhibitors of New Delhi metallo-β-lactamase (NDM-1): an in silico study.Molecular diversity · 2025Article
- Navigating the complexities of drug development for metallo-β-lactamase inhibitors.RSC medicinal chemistry · 2025Review
- Characterization of novel sequence type 12531 and O8:H7 serotype carbapenem-resistantAntimicrobial agents and chemotherapy · 2024Article
- Novel Variant of New Delhi Metallo-Beta-Lactamase (Antibiotics (Basel, Switzerland) · 2024Article
- Fluorescently Modified NDM-1: A Versatile Drug Sensor for RapidACS omega · 2024Article
- Molecular epidemiology and carbapenem resistance mechanisms ofFrontiers in microbiology · 2024Article
- Involvement of the non-active site Residues in the Catalytic Activity of NDM-4 Metallo beta-lactamase.The protein journal · 2023Article
- Tracking the Emergence and Dissemination of aMicrobiology spectrum · 2023Article
- Molecular Characteristics of an NDM-4 and OXA-181 Co-Producing K51-ST16 Carbapenem-Resistant Klebsiella pneumoniae: Study of Its Potential Dissemination Mediated by Conjugative Plasmids and Insertion Sequences.Antimicrobial agents and chemotherapy · 2023Article
- Comparison of Two Distinct Subpopulations of Klebsiella pneumoniae ST16 Co-Occurring in a Single Patient.Microbiology spectrum · 2022Article
- Resistance to aztreonam-avibactam due to CTX-M-15 in the presence of penicillin-binding protein 3 with extra amino acids inFrontiers in microbiology · 2022Article
- Molecular Epidemiology of New Delhi Metallo-Frontiers in microbiology · 2022Article
- Epidemiology of resistance of carbapenemase-producing Klebsiella pneumoniae to ceftazidime-avibactam in a Chinese hospital.Journal of applied microbiology · 2022Article
- Enzyme Inhibitors: The Best Strategy to Tackle Superbug NDM-1 and Its Variants.International journal of molecular sciences · 2021Review
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A clinical Escherichia coli isolate resistant to all β-lactams, including carbapenems, expressed a novel metallo-β-lactamase (MBL), NDM-4, differing from NDM-1 by a single amino acid substitution (Met154Leu). NDM-4 possessed increased hydrolytic activity toward carbapenems and several cephalosporins compared to that of NDM-1. This amino acid substitution was not located in the known active sites of NDM-1, indicating that remote amino acid substitutions might also play a role in the extended activity of this MBL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.